TP53 is a classic tumor suppressor gene that encodes the p53 protein and functions as a central regulator of cancer suppression, with the key fact here noting correction through homologous recombination. It is one of the most frequently mutated genes in human cancers and is repeatedly framed as a major therapeutic target in oncology, especially in settings where p53 dysfunction contributes to loss of apoptotic competence. Beyond cancer biology, TP53 is implicated in the myeloid malignancy phase of ercc6l2 disease, in the chromosomal instability subtype of alpha fetoprotein producing gastric cancer, and as a disease-driving partner in the MDM2-p53 interaction. Recent literature also highlights TP53-directed strategies such as CRISPR-mediated correction, CRISPR-supported curcumin nanoparticles that enhance expression, and broader p53-targeting approaches including MDM2/4 antagonists, p53-based genetic therapies, and p53-based tumor immunotherapy. Network pharmacology has additionally identified TP53 as a fever-related target linked to vernomenin, showing that its relevance extends beyond oncology-focused mechanisms. Overall, TP53 sits at the intersection of genome repair, apoptosis control, and protein-protein interaction targeting, making it a high-value node for precision therapeutics.
Cancer
- TP53 was described as the most frequently mutated gene in human cancers and a major therapeutic target in oncology. (PMID:41942427)
- Advanced tumors were reported to have dysfunctional TP53, contributing to loss of apoptotic competence and apoptosis resistance, including in non small cell lung cancer. (PMID:41655514)
- A 2026 review in Signal Transduction and Targeted Therapy summarized advances in p53 structure and therapeutic targeting, including MDM2/4 antagonists, p53-based genetic therapies, and p53-based tumor immunotherapy. (PMID:41942427)
- Macrocyclic peptides were highlighted as modulators of disease-driving PPIs such as MDM2-p53, reinforcing TP53 as a protein-interaction target. (PMID:42017321)
Genetic disease and hematologic malignancy
- TP53 was reported as the gene mutated in the myeloid malignancy phase of ercc6l2 disease. (PMID:41628318)
- Allogeneic hematopoietic stem cell transplantation in ERCC6L2 disease was discussed in Blood Advances, with TP53-mutated myeloid malignancy noted as part of disease progression. (PMID:41628318)
- CRISPR-mediated cancer therapy reviews described TP53 correction through homologous recombination as a direct gene-editing strategy. (PMID:41833894)
- The key fact that TP53 is a tumor suppressor target aligns with these correction-based approaches aimed at restoring function. (PMID:41833894)
Targeted delivery and gene modulation
- CRISPR-supported curcumin-loaded polymeric nanoparticles were designed to enhance TP53 expression. (PMID:41882965)
- An ultrasound-enhanced CRISPR-curcumin nanoparticle platform was reported for gene-modulating therapy in metastatic pulmonary lesions. (PMID:41882965)
- The CRISPR-mediated cancer therapies review emphasized direct tumor targeting approaches that include TP53 correction through homologous recombination. (PMID:41833894)
- These studies position TP53 as a practical target for nanoparticle-enabled gene modulation rather than only a diagnostic biomarker. (PMID:41882965)
Other disease associations and computational targeting
- TP53 mutations were described as part of the molecular signature often seen in alpha fetoprotein producing gastric cancer, particularly the chromosomal instability subtype. (PMID:41978393)
- A network pharmacology study identified TP53 as one of the fever-related targets linked to vernomenin. (PMID:41691789)
- The vernomenin study used computational profiling and molecular modeling, supporting TP53 as a predicted interaction node rather than a validated clinical target. (PMID:41691789)
- The macrocyclic peptide review further supports TP53-centered PPI targeting, especially through the MDM2-p53 axis. (PMID:42017321)